Literature DB >> 21633249

Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs.

Gong Zhao1, Erin Walsh, John C Shryock, Eric Messina, Yuzhi Wu, Dewan Zeng, Xiaobin Xu, Manuel Ochoa, Stephen P Baker, Thomas H Hintze, Luiz Belardinelli.   

Abstract

Effects of ranolazine alone and in the presence of phenylephrine (PE) or isoproterenol (ISO) on hemodynamics, coronary blood flow and heart rate (HR) in the absence and presence of hexamethonium (a ganglionic blocker) were studied in conscious dogs. Ranolazine (0.4, 1.2, 3.6, and 6 mg/kg, intravenous) alone caused transient (<1 minute) and reversible hemodynamic changes. PE (0.3-10 μg/kg) caused a dose-dependent increase in blood pressure and decrease in HR. ISO (0.01-0.3 μg/kg) caused a dose-dependent decrease in blood pressure and an increase in HR. Ranolazine at high (11-13 mM), but not at moderate (4-5 mM) concentrations partially attenuated changes in mean arterial blood pressure and HR caused by either PE or ISO in normal conscious dogs. However, in dogs treated with hexamethonium (20 mg/kg) to cause autonomic blockade, ranolazine (both 4-5 and 11-13 μM) significantly attenuated both the PE- and ISO-induced changes in mean arterial blood pressure. The results suggest that a potential antiadrenergic effect of ranolazine was masked by autonomic control mechanisms in conscious dogs but could be observed when these mechanisms were inhibited (eg, in the hexamethonium-treated dog). Ranolazine, at plasma concentrations <10 μM and in conscious dogs with intact autonomic regulation, had minimal antiadrenergic (α and β) effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21633249      PMCID: PMC5774223          DOI: 10.1097/FJC.0b013e31821458e8

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  15 in total

1.  Norepinephrine-induced beta 1-adrenergic peripheral vasodilation in conscious dogs.

Authors:  S F Vatner; D R Knight; T H Hintze
Journal:  Am J Physiol       Date:  1985-07

2.  Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine.

Authors:  L Belardinelli; J C Shryock; H Fraser
Journal:  Heart       Date:  2006-07       Impact factor: 5.994

Review 3.  A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies.

Authors:  John C Shryock; Yejia Song; Lin Wu; Heather Fraser; Luiz Belardinelli
Journal:  J Electrocardiol       Date:  2004       Impact factor: 1.438

4.  Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine.

Authors:  M C Allely; C M Brown; B A Kenny; A T Kilpatrick; A Martin; M Spedding
Journal:  J Cardiovasc Pharmacol       Date:  1993-06       Impact factor: 3.105

5.  Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.

Authors:  Yejia Song; John C Shryock; Lin Wu; Luiz Belardinelli
Journal:  J Cardiovasc Pharmacol       Date:  2004-08       Impact factor: 3.105

6.  Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.

Authors:  Benjamin M Scirica; David A Morrow; Hanoch Hod; Sabina A Murphy; Luiz Belardinelli; Chester M Hedgepeth; Peter Molhoek; Freek W A Verheugt; Bernard J Gersh; Carolyn H McCabe; Eugene Braunwald
Journal:  Circulation       Date:  2007-09-05       Impact factor: 29.690

7.  Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.

Authors:  Bernard R Chaitman
Journal:  J Cardiovasc Pharmacol Ther       Date:  2004-09       Impact factor: 2.457

8.  Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

Authors:  Bernard R Chaitman; Sandra L Skettino; John O Parker; Peter Hanley; Jaroslav Meluzin; Jerzy Kuch; Carl J Pepine; Whedy Wang; Jeanenne J Nelson; David A Hebert; Andrew A Wolff
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

Review 9.  Late sodium current inhibition as a new cardioprotective approach.

Authors:  Sharon L Hale; John C Shryock; Luiz Belardinelli; Michael Sweeney; Robert A Kloner
Journal:  J Mol Cell Cardiol       Date:  2008-04-08       Impact factor: 5.000

10.  Cardiovascular responses to the stimulation of alpha-1 and alpha-2 adrenoceptors in the conscious dog.

Authors:  O L Woodman; S F Vatner
Journal:  J Pharmacol Exp Ther       Date:  1986-04       Impact factor: 4.030

View more
  10 in total

1.  Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine.

Authors:  Serge Sicouri; Jonathan Blazek; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-03-09

2.  Ranolazine's sweet side--improvement of glycaemic control by the novel mechanism of skeletal muscle microvascular recruitment.

Authors:  Richard L Verrier
Journal:  J Physiol       Date:  2013-10-15       Impact factor: 5.182

3.  Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure.

Authors:  Guangqiu Feng; Yu Yang; Juan Chen; Zhiyong Wu; Yin Zheng; Wei Li; Wenxin Dai; Pin Guan; Chunrong Zhong
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.

Authors:  Raffaele Coppini; Luca Mazzoni; Cecilia Ferrantini; Francesca Gentile; Josè Manuel Pioner; Annunziatina Laurino; Lorenzo Santini; Valentina Bargelli; Matteo Rotellini; Gianluca Bartolucci; Claudia Crocini; Leonardo Sacconi; Chiara Tesi; Luiz Belardinelli; Jil Tardiff; Alessandro Mugelli; Iacopo Olivotto; Elisabetta Cerbai; Corrado Poggesi
Journal:  Circ Heart Fail       Date:  2017-03       Impact factor: 8.790

Review 5.  Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

6.  Myocyte repolarization modulates myocardial function in aging dogs.

Authors:  Andrea Sorrentino; Sergio Signore; Khaled Qanud; Giulia Borghetti; Marianna Meo; Antonio Cannata; Yu Zhou; Ewa Wybieralska; Marco Luciani; Ramaswamy Kannappan; Eric Zhang; Alex Matsuda; Andrew Webster; Maria Cimini; Elizabeth Kertowidjojo; David A D'Alessandro; Oriyanhan Wunimenghe; Robert E Michler; Christopher Royer; Polina Goichberg; Annarosa Leri; Edward G Barrett; Piero Anversa; Thomas H Hintze; Marcello Rota
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-22       Impact factor: 4.733

Review 7.  The role of late I Na in development of cardiac arrhythmias.

Authors:  Charles Antzelevitch; Vladislav Nesterenko; John C Shryock; Sridharan Rajamani; Yejia Song; Luiz Belardinelli
Journal:  Handb Exp Pharmacol       Date:  2014

Review 8.  Extended-release ranolazine: critical evaluation of its use in stable angina.

Authors:  Adriano Am Truffa; L Kristin Newby; Chiara Melloni
Journal:  Vasc Health Risk Manag       Date:  2011-08-25

9.  Ranolazine may exert its beneficial effects by increasing myocardial adenosine levels.

Authors:  D Elizabeth Le; Catherine M Davis; Kevin Wei; Yan Zhao; Zhiping Cao; Matthew Nugent; Kristin L Lyon Scott; Lijuan Liu; Shanthi Nagarajan; Nabil J Alkayed; Sanjiv Kaul
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-12-13       Impact factor: 4.733

10.  A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.

Authors:  C Noel Bairey Merz; Eileen M Handberg; Chrisandra L Shufelt; Puja K Mehta; Margo B Minissian; Janet Wei; Louise E J Thomson; Daniel S Berman; Leslee J Shaw; John W Petersen; Garrett H Brown; R David Anderson; Jonathan J Shuster; Galen Cook-Wiens; André Rogatko; Carl J Pepine
Journal:  Eur Heart J       Date:  2015-11-27       Impact factor: 35.855

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.